利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

275 条记录 (耗时 0.033 秒)

    Pharmaceutical compositions of rifaximin
    32.
    发明授权
    Pharmaceutical compositions of rifaximin 有权
    利福昔明的药物组合物

    公开(公告)号：US08383151B2

    公开(公告)日：2013-02-26

    申请号：US12144453

    申请日：2008-06-23

    申请人： Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    发明人： Harshal Anil Jahagirdar ,  Rajesh Kulkarni ,  Shirishkumar Kulkarni

    IPC分类号： A61K9/20

    CPC分类号： A61K31/44 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2086 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/4808 ,  Y02A50/473 ,  Y02A50/475

    摘要： A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.

    摘要翻译： 一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。 利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。 多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。 包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。 所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。

    NOVEL FUSION TAG OFFERING SOLUBILITY TO INSOLUBLE RECOMBINANT PROTEIN
    37.
    发明申请
    NOVEL FUSION TAG OFFERING SOLUBILITY TO INSOLUBLE RECOMBINANT PROTEIN 审中-公开
    新颖的融合标签提供不溶性重组蛋白的溶解性

    公开(公告)号：US20120107876A1

    公开(公告)日：2012-05-03

    申请号：US13318276

    申请日：2010-04-29

    申请人： Sampali Banerjee ,  Sriram Padmanabhan

    发明人： Sampali Banerjee ,  Sriram Padmanabhan

    IPC分类号： C12P21/02 ,  C12N15/70 ,  C07K14/00

    CPC分类号： C07K14/31 ,  C07K2319/35 ,  C07K2319/50

    摘要： The invention relates to a fusion tag comprising Serine-aspartic acid repeats of the well conserved region of the Staphylococcus aureus Sdr C gene superfamily. A START codon and an enterokinase cleavage site has been incorporated into this repeat region to make a novel fusion tag that is responsible for expressing soluble proteins in bacterial system.

    摘要翻译： 本发明涉及包含金黄色葡萄球菌Sdr C基因超家族的保守区域的丝氨酸 - 天冬氨酸重复序列的融合标签。 已经将START密码子和肠激酶切割位点并入该重复区域，以制备新的融合标签，其负责在细菌系统中表达可溶性蛋白质。

    Crystalline form of lamivudine
    38.
    发明授权
    Crystalline form of lamivudine 失效
    拉米夫定的结晶形式

    公开(公告)号：US08158607B2

    公开(公告)日：2012-04-17

    申请号：US12297174

    申请日：2007-02-09

    申请人： Girij Pal Singh ,  Dhananjai Srivastava ,  Manmeet Brijkishore Saini ,  Pritesh Rameshbhai Upadhyay

    发明人： Girij Pal Singh ,  Dhananjai Srivastava ,  Manmeet Brijkishore Saini ,  Pritesh Rameshbhai Upadhyay

    IPC分类号： A01N43/58 ,  A61K31/50 ,  A61K31/70 ,  C07D239/00 ,  C07D239/02

    CPC分类号： C07D411/04

    摘要： The disclosure herein relates to a new Lamivudine polymorphic form, methods of making the same, and pharmaceutical formulations thereof. A (−) cis-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one in the form of monoclinic crystals has characteristic powder X-ray diffractogram, as disclosed herein, is disclosed along with a process for preparation of the same. A pharmaceutical composition in solid dosage unit form comprising a therapeutically effective amount of a new Lamivudine polymorphic form in combination with a pharmaceutically acceptable carrier is also disclosed along with a pharmaceutical composition useful for treating HIV infections in humans.

    摘要翻译： 本文的公开内容涉及新的拉米夫定多晶型物，其制备方法及其药物制剂。 单斜晶体形式的（ - ）顺式-4-氨基-1-（2-羟甲基-1,3-氧硫杂环戊烷-5-基） - （1H） - 嘧啶-2-酮具有特征性粉末X射线衍射图 如本文所公开的，与其制备方法一起公开。 包含治疗有效量的新的拉米夫定多晶型物与药学上可接受的载体组合的固体剂量单位形式的药物组合物也与用于治疗人类HIV感染的药物组合物一起公开。

    STABLE AMORPHOUS FORM OF CARVEDILOL DIHYDROGEN PHOSPHATE WITH STABILIZER
    39.
    发明申请
    STABLE AMORPHOUS FORM OF CARVEDILOL DIHYDROGEN PHOSPHATE WITH STABILIZER 有权
    维生素D二磷酸稳定非晶形态

    公开(公告)号：US20110124879A1

    公开(公告)日：2011-05-26

    申请号：US12674642

    申请日：2008-08-06

    申请人： Rajesh Kumar Thaper ,  Manoj Devilalji Prabhavat ,  Yogesh Dadaji Pawar ,  Pritesh R. Upadhyay

    发明人： Rajesh Kumar Thaper ,  Manoj Devilalji Prabhavat ,  Yogesh Dadaji Pawar ,  Pritesh R. Upadhyay

    IPC分类号： C07D209/88

    CPC分类号： C07D209/88

    摘要： The present invention provides a novel stable amorphous form of carvedilol dihydrogen phosphate and the process for its preparation that involves reaction of carvedilol base with ortho phosphoric acid in the presence of stabilizer in a suitable solvent or mixture of solvents followed by concentration and isolation. An alternate process for preparation of amorphous form of carvedilol dihydrogen phosphate involves addition of stabiliser to the solution of stable amorphous or crystalline carvedilol dihydrogen phosphate in a suitable solvent or mixture of solvents followed by concentration and isolation. The novel stable amorphous form of carvedilol dihydrogen phosphate is highly stable.

    摘要翻译： 本发明提供了一种新颖的卡维地洛磷酸二氢不稳定形式及其制备方法，其中包括在稳定剂存在下，在合适的溶剂或溶剂混合物中将卡维地洛碱与原磷酸反应，随后浓缩和分离。 用于制备无定形形式的卡维地洛磷酸二氢盐的替代方法包括在合适的溶剂或溶剂混合物中将稳定剂加入稳定的无定形或结晶卡维地洛二磷酸盐溶液中，然后浓缩和分离。 卡维地洛磷酸二氢盐的新型稳定无定形形式是高度稳定的。